SecBot SecBot
Insider Cluster (2 insiders) ·Filed Aug 31, 2026

TRDA

Entrada Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed2mo ago
Insider cluster: 2 insiders, $383K total
Actionable Insight • Neutral

Monitor for any additional selling by MPM funds or emergence of C-suite insider activity. The selling is routine for venture investors and does not warrant immediate action, but continued large-scale sales could signal reduced conviction.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$7.07
T+0 close · Aug 31, 2026 · via day close
Latest settled
−10.18%
T+20 · $6.35 · next T+60 in 8d
Vs SPY
−10.50%
α at T+20
Latest observation
+7.08%
T+51 · FF3 residual α
  1. T+0 · Sep 1 $7.07entry
  2. T+1 · 3mo ago +3.25%α +2.81% · $7.30
  3. T+5 · 2mo ago +0.57%α +0.48% · $7.11
  4. T+20 · 7w ago −10.18%α −10.50% · $6.35
  5. T+53 · todayOpen
  6. T+60 · in 8d Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two MPM BioVentures funds (10% owners) sold a combined $383K in TRDA shares over a 7-day window, representing ~0.14% of market cap. This is a modest, routine sell-off by venture investors, not a bearish signal from C-suite insiders. The cluster is likely driven by portfolio rebalancing rather than negative company-specific information.

Key Financial Metrics

Direction
selling
Total Value
$383.0K
Insiders
2

Key Facts

  • Total insider sales: $383,000 across 7 trades
  • Sellers: MPM BioVentures 2014, L.P. and MPM BioVentures 2018, L.P. (both 10% owners)
  • Sales represent ~0.14% of TRDA's $273M market cap
  • No C-suite executives involved in the cluster
  • Recent 30-day insider activity shows $2.2M in total sales

Financial Impact

Modest insider selling of $383K, ~0.14% of market cap

insider ownership

Risk Factors

  • Further selling by MPM funds could pressure the stock
  • No C-suite buying to offset the selling sentiment

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-TRDA-1788215204770

Track record

21 reports on TRDA

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +58.22% at T+20 after the May 4, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  2. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $4.55 Now $5.00 +9.89% settles Feb 3
  3. Oct 14, 20264w ago 8-K Bullish 6/10 Entry $4.55 Now $5.00 +9.89% settles Jan 11
  4. Sep 9, 20269w ago Insider Cluster Bearish 6/10 Entry $6.42 Now $5.00 +22.12% settles Dec 4
  5. Sep 3, 202610w ago Insider Cluster Neutral 3/10 Entry $7.13 Now $5.00 −29.87% settles Dec 1
  6. Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
  7. Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
  8. Aug 31, 202611w ago Insider Cluster Neutral 3/10 Viewing Entry $7.07 Now $5.00 −29.28% settles Nov 25
  9. Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $7.27 Now $5.00 −31.22% settles Nov 20
  10. Aug 10, 202614w ago Insider Cluster Neutral 2/10 Entry $7.04 to $5.06 Now $5.00 −28.98% ▼ −28.13% −27.64% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 31, 2026